Procedures required to accomplish complete cytoreduction of ovarian cancer: Is there a correlation with "biological aggressiveness" and survival?

被引:119
作者
Eisenkop, SM
Spirtos, NM
机构
[1] Womens Canc Ctr, Palo Alto, CA 94304 USA
[2] Womens Canc Ctr, Tarzana, CA 91356 USA
关键词
D O I
10.1006/gyno.2001.6313
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective. The aim of this study was to determine if the necessity of using specific procedures to attain complete cytoreduction in ovarian cancer correlates with innate biologic aggressiveness and independently influences survival. Methods. Between 1990 and 2000, 213 patients with Stage IIIC epithelial ovarian cancer underwent complete cytoreduction before initiation of systemic platinum-based combination chemotherapy. Survival was stratified and analyzed (log rank and Cox regression) on the basis of whether extrapelvic bowel resection, diaphragm stripping, full-thickness diaphragm resection, modified posterior pelvic exenteration, peritoneal implant ablation and/or aspiration, and excision of grossly involved retroperitoneal lymph nodes were necessary to attain a visibly disease-free cytoreductive outcome. Results. The median and estimated 5-year survival for the cohort were 75.8 months and 54%, respectively. Survival was influenced (log rank) by the requirement of diaphragm stripping (required, median 42 months vs not required, median 79 months; P = 0.03) and the extent of mesenteric and serosal implants that required removal (none, median not reached, vs 1-50 implants, median not reached, vs >50 implants, median 40 months; P = 0.002). Survival was independently influenced (Cox regression) only by the extent of peritoneal metastatic implants that required removal (P = 0.01). The other investigated procedures and type of chemotherapy used did not influence survival. Conclusions. The need to remove a large number of peritoneal implants correlates with biological aggressiveness and diminished survival, but not significantly enough to preclude long-term survival or justify abbreviation of the operative effort. The need to use the other investigated procedures had minimal or no observed influence on survival. (C) 2001 Academic Press.
引用
收藏
页码:435 / 441
页数:7
相关论文
共 26 条
[1]   Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer [J].
Alberts, DS ;
Liu, PY ;
Hannigan, EV ;
OToole, R ;
Williams, SD ;
Young, JA ;
Franklin, EW ;
ClarkePearson, DL ;
Malviya, VK ;
DuBeshter, B ;
Adelson, MD ;
Hoskins, WJ .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (26) :1950-1955
[2]  
BENEDETTIPANICI P, 1991, INT J GYNECOL CANCER, V133, P1
[3]   ELECTROSURGICAL DEBULKING OF OVARIAN-CANCER - A NEW TECHNIQUE USING THE ARGON BEAM COAGULATOR [J].
BRAND, E ;
PEARLMAN, N .
GYNECOLOGIC ONCOLOGY, 1990, 39 (02) :115-118
[4]   Critique of surgical cytoreduction in advanced ovarian cancer [J].
Covens, AL .
GYNECOLOGIC ONCOLOGY, 2000, 78 (03) :269-274
[5]   DEBULKING SURGERY FOR OVARIAN-CANCER WITH THE CAVITRON ULTRASONIC SURGICAL ASPIRATOR (CUSA) - A PRELIMINARY-REPORT [J].
DEPPE, G ;
MALVIYA, VK ;
MALONE, JM .
GYNECOLOGIC ONCOLOGY, 1988, 31 (01) :223-226
[6]   PERITONEAL IMPLANT ELIMINATION DURING CYTOREDUCTIVE SURGERY FOR OVARIAN-CANCER - IMPACT ON SURVIVAL [J].
EISENKOP, SM ;
NALICK, RH ;
WANG, HJ ;
TENG, NNH .
GYNECOLOGIC ONCOLOGY, 1993, 51 (02) :224-229
[7]   Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: A prospective study [J].
Eisenkop, SM ;
Friedman, RL ;
Wang, HJ .
GYNECOLOGIC ONCOLOGY, 1998, 69 (02) :103-108
[8]  
EISENKOP SM, 1991, OBSTET GYNECOL, V78, P879
[9]   THE IMPACT OF SUBSPECIALTY TRAINING ON THE MANAGEMENT OF ADVANCED OVARIAN-CANCER [J].
EISENKOP, SM ;
SPIRTOS, NM ;
MONTAG, TW ;
NALICK, RH ;
WANG, HJ .
GYNECOLOGIC ONCOLOGY, 1992, 47 (02) :203-209
[10]   THE INFLUENCE OF TUMOR GRADE, DISTRIBUTION, AND EXTENT OF CARCINOMATOSIS IN MINIMAL RESIDUAL STAGE-III EPITHELIAL OVARIAN-CANCER AFTER OPTIMAL PRIMARY CYTOREDUCTIVE SURGERY [J].
FARIASEISNER, R ;
TENG, F ;
OLIVEIRA, M ;
LEUCHTER, R ;
KARLAN, B ;
LAGASSE, LD ;
BEREK, JS .
GYNECOLOGIC ONCOLOGY, 1994, 55 (01) :108-110